The rate of tumor growth during treatment accurately predicts the FDA gold standard of overall survival [OS] in a broad range of malignancies.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Columbia University Irving Medical Center, U.S. National Science Foundation, Hebrew University of Jerusalem, NewYork–Presbyterian Hospital, Columbia University, Hospital General Universitario Gregorio Marañón, Project Data Sphere, National Institutes of Health, National Cancer Institute, James J. Peters VA Medical Center
Language: English
Subfield: Modeling and Simulation
Field: Mathematics
Domain: Physical Sciences
Open Access status: closed
OpenAlex ID: W2891953603
